Back to top

Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $275.00. According to TipRan...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ)